Pomerantz Appointed Lead Counsel in Orphazyme Securities Litigation

On September 13, 2021, U.S. District Judge Gary Feinerman of the Northern District of Illinois (Eastern Division) appointed Pomerantz LLP as Lead Counsel for the Class on behalf of Marko Busic, the Lead Plaintiff in Busic v. Orphazyme A/S et al., 21-cv-3640 (N.D. Ill.), a securities action brought on behalf of a class of defrauded investors concerning allegations related to the efficacy and commercial prospects for Orphazyme A/S’s lead drug candidate arimoclomol. Orphazyme is a biopharmaceutical company that develops therapies for the treatment of neurodegenerative orphan diseases.